论文部分内容阅读
目的：研究苯氧芳酸类降脂药苯扎贝特（ｂｅｚａｆｉｂｒａｔｅ）对血小板功能的影响。方法：分别在体内、外观察２８例高胆固醇血症（ＨＣ）患者血小板聚集试验（ＰＡｇＴ）、凝血口恶烷Ｂ２（ＴＸＢ２）及环腺苷酸（ｃＡＭＰ）在苯扎贝特作用前后的含量变化，并与１０例健康体检者对照。结果：口服苯扎贝特８周，血清总胆固醇（ＴＣ）、低密度脂蛋白胆固醇（ＬＤＬＣｈ）水平下降，ＰＡｇＴ、血小板ＴＸＢ２及ｃＡＭＰ含量无改变；不同浓度的苯扎贝特（６．９μｍｏｌ·Ｌ－１，６９μｍｏｌ·Ｌ－１）在体外对上述血小板功能指标无影响。结论：苯扎贝特在体内、外未发现有抗血小板的作用。
Objective: To investigate the effect of bezafibrate, a phenoxy aromatic lipid-lowering drug, on platelet function. Methods: The contents of PAgT, TXB2 and cAMP in 28 patients with hypercholesterolemia (HC) before and after bezafibrate were determined in vitro and in vivo respectively. Change, and with 10 cases of healthy people control. Results: After 8 weeks of oral administration of bezafibrate, serum total cholesterol (TC), low density lipoprotein cholesterol (LDLCh) levels were decreased, PAgT, TXB2 and cAMP contents of platelets were unchanged; different concentrations of bezafibrate (6) 9μmol·L-1,69μmol·L-1) had no effect on the above platelet function in vitro. Conclusion: Bezafib has no anti-platelet effect in vivo and in vitro.